TWST vs. IMCR, ACLX, DNLI, IOVA, SWTX, VCEL, RXRX, APGE, KYMR, and ADMA
Should you be buying Twist Bioscience stock or one of its competitors? The main competitors of Twist Bioscience include Immunocore (IMCR), Arcellx (ACLX), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), SpringWorks Therapeutics (SWTX), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), Kymera Therapeutics (KYMR), and ADMA Biologics (ADMA). These companies are all part of the "biological products, except diagnostic" industry.
Twist Bioscience (NASDAQ:TWST) and Immunocore (NASDAQ:IMCR) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations, institutional ownership and risk.
Twist Bioscience received 41 more outperform votes than Immunocore when rated by MarketBeat users. However, 70.59% of users gave Immunocore an outperform vote while only 56.69% of users gave Twist Bioscience an outperform vote.
In the previous week, Immunocore had 15 more articles in the media than Twist Bioscience. MarketBeat recorded 20 mentions for Immunocore and 5 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 0.74 beat Immunocore's score of 0.13 indicating that Twist Bioscience is being referred to more favorably in the media.
Twist Bioscience has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.
Twist Bioscience presently has a consensus price target of $42.50, indicating a potential downside of 9.59%. Immunocore has a consensus price target of $81.85, indicating a potential upside of 53.59%. Given Immunocore's higher possible upside, analysts plainly believe Immunocore is more favorable than Twist Bioscience.
Immunocore has a net margin of -22.60% compared to Twist Bioscience's net margin of -69.24%. Immunocore's return on equity of -16.54% beat Twist Bioscience's return on equity.
Immunocore has lower revenue, but higher earnings than Twist Bioscience. Immunocore is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.
84.5% of Immunocore shares are held by institutional investors. 3.9% of Twist Bioscience shares are held by insiders. Comparatively, 9.1% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Immunocore beats Twist Bioscience on 12 of the 18 factors compared between the two stocks.
Get Twist Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TWST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Twist Bioscience Competitors List
Related Companies and Tools
